What sets ZYDELIG apart?
ZYDELIG is approved for use in follicular B-cell non-Hodgkin lymphoma when the disease worsens after treatment with at least 2 prior medicines. ZYDELIG was approved based on response rates. Data are not yet available to show if ZYDELIG improves symptoms or survival.
ZYDELIG is approved for use in combination with Rituxan® (rituximab) when CLL comes back after prior cancer treatment and when Rituxan treatment alone may be used due to other health problems.
ZYDELIG is approved for use in small lymphocytic lymphoma (SLL) when the disease worsens after treatment with at least 2 prior medicines. ZYDELIG was approved based on response rates. Data are not yet available to show if ZYDELIG improves symptoms or survival.
ZYDELIG should not be used as the first medicine to treat people who have been diagnosed with CLL, follicular lymphoma, or SLL, and should not be used in combination with bendamustine and/or Rituxan to treat people with follicular lymphoma.
References: